Assessing Comparative Efficacy of Biologics for the Treatment of Psoriasis With Nail Involvement: A Systematic Review

Overview

Journal J Psoriasis Psoriatic Arthritis

Date 2024 Sep 19

PMID 39295894

Authors

Madiha Khan

Carly E Wallace

Fahad Ahmed

Syed Minhaj Rahman

Nashwah Memon

Adel Haque

Affiliations

Soon will be listed here.

Abstract

Background: Despite recent advances in biologics, there is a lack of significant evidence regarding the comparative efficacy of biologics in treating more resistant features of psoriasis, namely nail psoriasis. A systematic review synthesizing data from multiple studies is efficacious in assessing the comparative efficacy among biologics for the treatment of nail psoriasis.

Objective: To evaluate and compare the efficacy of biologics for the treatment of nail psoriasis.

Methods: Utilizing PRISMA guidelines, a systematic literature review was conducted using the Pubmed database on November 16, 2022. Studies selected were phase 3 or 4 randomized clinical trials, clinical studies, or other randomized trials with data on the treatment with biologics for adults with nail psoriasis.

Results: Sixteen studies meeting inclusion criteria were included for analysis. At 24 weeks, the highest mean NAPSI percent improvement achieved at week 24 was by brodalumab (76.9%) followed by etanercept (74%) and ixekizumab (70.5%) while the biologics achieving the greatest proportion of NAPSI 0 were adalimumab (44.6%) and ixekizumab (41%).

Conclusions: This study helps elucidate the comparative efficacy of biologics for the treatment of nail psoriasis. This review suggests that brodalumab and etanercept are associated with the highest percent improvement in nail psoriasis while adalimumab and ixekizumab are associated with the greatest probability of complete nail resolution.

References

Huang I, Wu P, Yang T, Li H, Huang Y, Cheng Y . Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis. J Am Acad Dermatol. 2021; 85(1):135-143. DOI: 10.1016/j.jaad.2021.01.024. View

Mease P, Smolen J, Behrens F, Nash P, Liu Leage S, Li L . A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2019; 79(1):123-131. PMC: 6937408. DOI: 10.1136/annrheumdis-2019-215386. View

Kristensen L, Keiserman M, Papp K, McCasland L, White D, Lu W . Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2021; 81(2):225-231. PMC: 8762015. DOI: 10.1136/annrheumdis-2021-221019. View

Mease P, van der Heijde D, Ritchlin C, Okada M, Cuchacovich R, Shuler C . Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled.... Ann Rheum Dis. 2016; 76(1):79-87. PMC: 5264219. DOI: 10.1136/annrheumdis-2016-209709. View

Reich K, Conrad C, Kristensen L, Smith S, Puig L, Rich P . Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatolog Treat. 2021; 33(3):1652-1660. DOI: 10.1080/09546634.2021.1892024. View

Mease P, Fleischmann R, Deodhar A, Wollenhaupt J, Khraishi M, Kielar D . Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2013; 73(1):48-55. PMC: 3888622. DOI: 10.1136/annrheumdis-2013-203696. View

Armstrong A, Puig L, Joshi A, Skup M, Williams D, Li J . Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020; 156(3):258-269. PMC: 7042876. DOI: 10.1001/jamadermatol.2019.4029. View

Wasel N, Thaci D, French L, Conrad C, Dutronc Y, Gallo G . Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb). 2020; 10(4):663-670. PMC: 7367982. DOI: 10.1007/s13555-020-00383-x. View

Zhang X, Xie B, He Y . Efficacy of Systemic Treatments of Nail Psoriasis: A Systemic Literature Review and Meta-Analysis. Front Med (Lausanne). 2021; 8:620562. PMC: 7902784. DOI: 10.3389/fmed.2021.620562. View

10.

Rich P, Griffiths C, Reich K, Nestle F, Scher R, Li S . Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2007; 58(2):224-31. DOI: 10.1016/j.jaad.2007.07.042. View

11.

Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester G . Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017; 389(10086):2317-2327. DOI: 10.1016/S0140-6736(17)31429-0. View

12.

Sawyer L, Cornic L, Levin L, Gibbons C, Moller A, Jemec G . Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2018; 33(2):355-366. PMC: 6587780. DOI: 10.1111/jdv.15277. View

13.

Blauvelt A, Papp K, Griffiths C, Randazzo B, Wasfi Y, Shen Y . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active.... J Am Acad Dermatol. 2017; 76(3):405-417. DOI: 10.1016/j.jaad.2016.11.041. View

14.

Ortonne J, Paul C, Berardesca E, Marino V, Gallo G, Brault Y . A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2012; 168(5):1080-7. DOI: 10.1111/bjd.12060. View

15.

van der Heijde D, Gladman D, Kishimoto M, Okada M, Rathmann S, Moriarty S . Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). J Rheumatol. 2017; 45(3):367-377. DOI: 10.3899/jrheum.170429. View

16.

Cassell S, Bieber J, Rich P, Tutuncu Z, Lee S, Kalunian K . The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007; 34(1):123-9. View

17.

Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M . Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2018; 181(5):954-966. DOI: 10.1111/bjd.17351. View

18.

Kavanaugh A, McInnes I, Mease P, Krueger G, Gladman D, Gomez-Reino J . Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009; 60(4):976-86. DOI: 10.1002/art.24403. View

19.

Elewski B, Rich P, Lain E, Soung J, Lewitt G, Jacobson A . Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020; 33(1):261-265. DOI: 10.1080/09546634.2020.1749546. View

20.

Reich K, Armstrong A, Foley P, Song M, Wasfi Y, Randazzo B . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III,.... J Am Acad Dermatol. 2017; 76(3):418-431. DOI: 10.1016/j.jaad.2016.11.042. View